Home > Historical Performance > Historical Transaction Report

Transaction Details

Company: ICON
Ticker:iclr
Yahoo Beta:0.49
Industry:biotechnology and drugs

Company Description:  ICON plc is a contract research organization that supports phase 1 through phase 4 clinical trials for new drugs. ICON, the number 4 CRO world-wide, is based in Ireland.

Purchase Date:01 Oct 2014 Sale Date:26 Mar 2015
Purchase Price:$55.79 Sale Price:$69.25
  --Split Adjusted:$55.79  --Split Adjusted:$69.25
Shares Purchased:140 Shares Sold:140
  --Split Adjusted:140  --Split Adjusted:140
Transaction Fee:$6.95 Transaction Fee:$4.60
Price Range (6 Months Prior):    Price Range (6 Months After):    
High$57.51 High$0.00
Date29 Sep 2014 Date01 Jan 1996
Low$46.07 Low$0.00
Date17 Jul 2014 Date01 Jan 1996
S&P (Purchase Date):$1,946.17 S&P (Sale Date):$2,056.15

Purchase
Timing:  We bought near the six month high.
Reason:  The combination of best-in-class technology, rapid historical growth, and advantageous consolidation opportunities made ICON an attractive buy.

Sale
Timing:  0
Reason:  We sold to limit ICON exposure to 10% of our total portfolio value.

S&P Gain: 5.65 % Annualized Gain: 14.84%
Stock Gain: 24.13 % Annualized Gain: 72.31%

Dividends:$0.00
Net Holding Return ($): $1,872.85
Net Holding Return (%): 23.96 %